Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche par promoteur : Genzyme
Femme et Homme Max 99 ans
Genzyme Europe BV
MAJ Il y a 4 ans
Study to Evaluate the Dose, Safety and Effectiveness of Modified-Release Recombinant Human Thyroid Stimulating Hormone (MRrhTSH) When Used in Conjunction with Radioiodine for the Treatment of Multinodular Goiter
The objective of this study is to determine the dose-response and safety of 2 doses of MRrhTSH with radioiodine (131I) therapy to achieve goiter shrinkage and improve goiter symptoms compared with 131...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Genzyme Corporation
MAJ Il y a 4 ans
NeoGAA Extension Study
Long-term safety and pharmacokinetics (PK) of neoGAA
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Genzyme Corporation
MAJ Il y a 4 ans
Evaluation of efficacy and safety of vandetanib in patients with advanced papillary or poorly differentiated thyroid cancer
To determine the efficacy (as assessed by progression free survival (PFS) ) of vandetanib when compared to placebo in patients with differentiated thyroid cancer that is either locally advanced or met...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Genzyme Europe B.V
MAJ Il y a 4 ans
A Prospective Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of Mipomersen in Patients With Severe Hypercholesterolemia on a Maximally Tolerated Lipid-Lowering Regimen and Who are Not on Apheresis
To compare the safety and efficacy of 26 weekly, subcutaneous injections of mipomersen (200 mg) against placebo in treating severely hypercholesterolemic patients who are on a maximally tolerated lipi...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Homme Max 99 ans
Genzyme Corporation
MAJ Il y a 4 ans
Evaluate the Safety, Pharmacodynamics, Pharmacokinetics, and Exploratory Efficacy of GZ402671 in Treatment-naïve Adult Male Patients with Fabry Disease
To assess the safety, pharmacokinetics (PK), pharmacodynamics (PD), and exploratory efficacy of GZ402671 / SAR402671 in enzyme replacement therapy treatment-naïve adult male patients diagnosed with ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Genzyme Europe BV
MAJ Il y a 4 ans
A Randomized, Double-Blind, Multicenter, Multinational, Placebo-Controlled Study of the Safety, Efficacy, and Pharmacokinetics of Myozyme, Recombinant Human Acid alpha-Glucosidase (rhGAA), Treatment in Patients with Late-Onset Pompe Disease
The overall objective is to evaluate the safety, efficacy, and pharmacokinetics (PK) of Myozyme treatment in patients with late-onset Pompe disease as compared to placebo. The primary objectives of...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Genzyme Europe BV
MAJ Il y a 4 ans
A Multicenter, Open-Label Study of Hectorol (doxercalciferol capsules) for the Treatment of Secondary Hyperparathyroidism in Stage 3 or Stage 4 Chronic Kidney Disease (CKD) Patients
To evaluate the safety and tolerability of Hectorol Capsules during 52 weeks of treatment in patients with Stage 3 or Stage 4 CKD
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme
Entre 55 ans
et 99 ans
Genzyme
MAJ Il y a 4 ans
GENZYME CLO34100405 : Essai de phase 3, randomisé en double aveugle, comparant l’efficacité et la tolérance de la cytarabine associée ou non à de la clofarabine, chez des patients âgés ayant une leucémie aiguë myéloïde. [Informations issues du site clinicaltrials.gov et traduites par l'INCa] [essai clos aux inclusions]
A phase III randomized, double-blind, controlled study comparing clofarabine and cytarabine versus cytarabine alone in adult patients 55 years and older with acute myelogenous leukemia (AML) who have ...
Pays
France
Organes
Leucémies aiguës
Spécialités
Chimiothérapie
,
Gériatrie
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Genzyme Corporation
MAJ Il y a 4 ans
Open Label Study of Sargramostim Among Patients Receiving Myelosuppressive Induction Chemotherapy for Acute Myelogenous Leukemia
Measure the proportion of patients who develop binding and neutralizing antibodies in the blood after treatment with sargramostim following induction/reinduction chemotherapy.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Genzyme GmbH
MAJ Il y a 4 ans
The Effectiveness of an Additional Course of Alemtuzumab in Relapsing Remitting Multiple Sclerosis Patients After 2 Courses of Alemtuzumab
Evaluation of effectiveness of an additional alemtuzumab course in patients with relapsing remitting multiple sclerosis (RRMS) with disease activity after 2 courses.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Précédent
1
2
3
4
5
6
Suivant